CD4+ cytotoxic T cells: an emerging effector arm of anti-tumor immunity

키워드

참고문헌 (58)

1. Zhou L, "Plasticity of CD4+ T cell lineage differentiation", Immunity, 30, pp.646~655 (2009)
2. Zhu J, "Differentiation of effector CD4 T cell populations(*)", Annu Rev Immunol, 28, pp.445~489 (2010)
3. Zappasodi R, "Emerging concepts for immune checkpoint blockade-based combination therapies", Cancer Cell, 33, pp.581~598 (2018)
4. Barrett DM, "Chimeric antigen receptor therapy for cancer", Annu Rev Med, 65, pp.333~347 (2014)
5. Ott PA, "Combination immunotherapy : a road map", J Immunother Cancer, 5, pp.16~ (2017)
6. Johnson DB, "Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1", PD-L1therapy, 2016, pp.7, 10582~
7. Rodig SJ, "MHC proteins confer differential sensitivity to CTLA-4 and PD-1blockade in untreated metastatic melanoma", Sci Transl Med, 10, pp.eaar3342~ (2018)
8. Johnson DB, "Quantitative spatial profiling of PD-1", PD-L1 interaction and HLA-DR, Clin Cancer Res, pp.2018, 24[DOI]
9. Park IA, "Expression of the MHC class II in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and interferon signaling", PLoS One, 12, pp.e0182786~ (2017)
10. Loi S, "RAS", MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer : therapeutic cooperation between MEK and PD-1, Clin Cancer Res, pp.2016, 22[DOI]
11. Michel S, "Lack of HLA class II antigen expression in microsatellite unstable colorectal carcinomas is caused by mutations in HLA class II regulatory genes", Int J Cancer, 127, pp.889~898 (2010)
12. Bustin SA, "Expression of HLA class II in colorectal cancer : evidence for enhanced immunogenicity of microsatellite-instability-positive tumours", Tumour Biol, 22, pp.294~298 (2001)
13. Callahan MJ, "Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer", Clin Cancer Res, 14, pp.7667~7673 (2008)
14. Turner TB, "Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth", Oncotarget, 8, pp.44159~44170 (2017)
15. Younger AR, "HLA class II antigen presentation by prostate cancer cells", Prostate Cancer Prostatic Dis, 11, pp.334~341 (2008)
16. Roemer MGM, "Major histocompatibility complex class ii and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic hodgkin lymphoma", J Clin Oncol, 36, pp.942~950 (2018)
17. Soos JM, "Malignant glioma cells use MHC class II transactivator(CIITA)promoters III and IV to direct IFN-gamma-inducible CIITA expression and can function as nonprofessional antigen presenting cells in endocytic processing and CD4(+)T-cell activation", Glia, 36, pp.391~405 (2001)
18. Yazawa T, "Lack of class II transactivator causes severe deficiency of HLA-DR expression in small cell lung cancer", J Pathol, 187, pp.191~199 (1999)
19. Quezada SA, "Tumorreactive CD4(+)T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts", J Exp Med, 207, pp.637~650 (2010)
20. Xie Y, "Naive tumorspecific CD4(+)T cells differentiated in vivo eradicate established melanoma", J Exp Med, 207, pp.651~667 (2010)
21. Hirschhorn-Cymerman D, "Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype", J Exp Med, 209, pp.2113~2126 (2012)
22. Curran MA, "Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin", J Exp Med, 210, pp.743~755 (2013)
23. Kitano S, "Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients", Cancer Immunol Res, 1, pp.235~244 (2013)
24. Puram SV, "Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer", Cell, 171, pp.1611~1624 (2017)
25. Azizi E, "Single-cell map of diverse immune phenotypes in the breast tumor microenvironment", Cell, 174, pp.1293~1308 (2018)
26. Zhang Y, "Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer", Cancer Cell, 39, pp.1578~1593 (2021)
27. Guo X, "Global characterization of T cells in non-small-cell lung cancer by singlecell sequencing", Nat Med, 24, pp.978~985 (2018)
28. Zhang L, "Lineage tracking reveals dynamic relationships of T cells in colorectal cancer", Nature, 564, pp.268~272 (2018)
29. Zhang Q, "Landscape and dynamics of single immune cells in hepatocellular carcinoma", Cell, 179, pp.829~845e820 (2019)
30. Zheng C, "Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing", Cell, 169, pp.1342~1356e1316 (2017)
31. Oh DY, "Intratumoral CD4(+)T cells mediate anti-tumor cytotoxicity in human bladder cancer", Cell, 181, pp.1612~1625e1613 (2020)
32. Tang XX, "Clinical relevance of CD4 cytotoxic T cells in high-risk neuroblastoma", Front Immunol, 12, pp.650427~ (2021)
33. Zhou Y, "Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma", Nat Commun, 11, pp.6322~ (2020)
34. Porakishvili N, "Cytotoxic CD4+ T cells in patients with B cell chronic lymphocytic leukemia kill via a perforin-mediated pathway", Haematologica, 89, pp.435~443 (2004)
35. Khanna R, "Class I processing-defective Burkitt’s lymphoma cells are recognized efficiently by CD4+ EBV-specific CTLs", J Immunol, 158, pp.3619~3625 (1997)
36. Cader FZ, "A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma", Nat Med, 26, pp.1468~1479 (2020)
37. Cachot A, "Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer", Sci Adv, 7, pp.eabe3348~ (2021)
38. Hu Z, "Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma", Nat Med, 27, pp.515~525 (2021)
39. Melenhorst JJ, "Decadelong leukaemia remissions with persistence of CD4(+)CAR T cells", Nature, 602, pp.503~509 (2022)
40. Choi IK, "Signaling by the Epstein-Barr virus LMP1 protein induces potent cytotoxic CD4(+)and CD8(+)T cell responses", Proc Natl Acad Sci U S A, 115, pp.E686~ (2018)
41. Choi IK, "Mechanism of EBV inducing anti-tumour immunity and its therapeutic use", Nature, 590, pp.157~162 (2021)
42. Sledzinska A, "Regulatory T cells restrain interleukin-2-and blimp-1-dependent acquisition of cytotoxic function by CD4(+)T cells", Immunity, 52, pp.151~166 (2020)
43. Takeuchi A, "CRTAM determines the CD4+ cytotoxic T lymphocyte lineage", J Exp Med, 213, pp.123~138 (2016)
44. Brown DM, "IL-2 and antigen dose differentially regulate perforin-and FasL-mediated cytolytic activity in antigen specific CD4+ T cells", Cell Immunol, 257, pp.69~79 (2009)
45. Cruz-Guilloty F, "Runx3 and T-box proteins cooperate to establish the transcriptional program of effector CTLs", J Exp Med, 206, pp.51~59 (2009)
46. Serroukh Y, "The transcription factors Runx3 and ThPOK crossregulate acquisition of cytotoxic function by human Th1lymphocytes", Elife, 7, pp.e30496~ (2018)
47. Lancki DW, "Mechanisms of lysis by cytotoxic T lymphocyte clones. Lytic activity and gene expression in cloned antigen-specific CD4+and CD8+ T lymphocytes", J Immunol, 146, pp.3242~3249 (1991)
48. Akhmetzyanova I, "CD137 agonist therapy can reprogram regulatory T cells into cytotoxic CD4+ T cells with antitumor activity", J Immunol, 196, pp.484~492 (2016)
49. Appay V, "Characterization of CD4(+)CTLs ex vivo", J Immunol, 168, pp.5954~5958 (2002)
50. Takeuchi A, "CD4 CTL, a cytotoxic subset of CD4(+)T cells, their differentiation and function", Front Immunol, 8, pp.194~ (2017)
51. Waight JD, "Selective fcgammar co-engagement on APCs modulates the activity of therapeutic antibodies targeting T cell antigens", Cancer Cell, 33, pp.1033~1047 (2018)
52. Braumuller H, "T-helper-1-cell cytokines drive cancer into senescence", Nature, 494, pp.361~365 (2013)
53. Kammertoens T, "Tumour ischaemia by interferon-gamma resembles physiological blood vessel regression", Nature, 545, pp.98~102 (2017)
54. Corthay A, "Primary antitumor immune response mediated by CD4+ T cells", Immunity, 22, pp.371~383 (2005)
55. Kennedy R, "Multiple roles for CD4+ T cells in anti-tumor immune responses", Immunol Rev, 222, pp.129~144 (2008)
56. Haabeth OAW, "CD4+ T-cell killing of multiple myeloma cells is mediated by resident bone marrow macrophages", Blood Adv, 4, pp.2595~2605 (2020)
57. Steimle V, "Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA", Science, 265, pp.106~109 (1994)
58. Neefjes J, "Towards a systems understanding of MHC class I and MHC class II antigen presentation", Nat Rev Immunol, 11, pp.823~836 (2011)

관련 논문AI추천